Pharma Journalist -

Archeus Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting…
Read More...

Health Canada has approved Novartis' KISQALI (ribociclib tablets) in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive (HR+),…
Read More...

Advarra announced the launch of the Council for Responsible Use of AI in Clinical Trials. The Council, which includes leaders from across the life sciences industry, will focus on…
Read More...

RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an…
Read More...

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) as a pre-exposure prophylaxis (PrEP) to prevent sexually acquired HIV-1.…
Read More...

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying…
Read More...

Ferrer has announced that its investigational therapy FNP-223, developed to treat progressive supranuclear palsy (PSP), has received Fast Track designation from the U.S. Food and Drug…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of…
Read More...

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, launches from stealth having raised a total of $140 million (£107…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational drug DYNE-101 for the treatment of…
Read More...